Latest Articles and Analysis

Analyzes the role of contract pharmacies and intermediaries in 340B drug distribution and patient access.

Examines how 340B program expansion correlates with declining hospital charity care for vulnerable patients.

Explores accountability mechanisms in the 340B program and oversight requirements for patient protection.

Explains why transparency in 340B operations is critical for program integrity and patient access.

Introduces the 340B Drug Discount Program: its history, purpose, and significance for medication access.

Payers restrict HCV treatment through utilization management; patient assistance programs fill the critical gap.

Analyzes Biden health policy priorities including drug pricing reform and Medicare expansion.

Overview of the 340B Drug Discount Program for patient advocates covering program history and key policy issues.

Calls for restoring Obama-era guidance defining 340B patient protections and enforcement mechanisms.

Examines CMS's rebate rule on copay accumulator programs that block patient assistance from counting toward deductibles.

Reviews Biden's first 100 days on healthcare: infrastructure, subsidies, harm reduction, and health equity.

Quarterly update on HCV treatment coverage across ADAPs, Medicaid, Veterans programs, and patient assistance options.

Quarterly Watch covering HCV treatment access across ADAPs and Medicaid, harm reduction programs, and COVID-19 impact on care.

Final rule allowing drug importation from Canada poses safety risks from counterfeit medications.

CANN outlines advocacy priorities for the Biden era, from 340B reform and drug pricing to HIV criminalization and health equity.